Scholars Central

Conference abstractPublished 3 Nov 2015

Cyclodextrin as enhancer of targeting ability of folate-decorated polyethylenglycol-polycaprolactone nanoparticles to solid tumors

Authors: C Conte, I Fotticchia, F Moret, C Giancola, E Reddi, F Ungaro, F Quaglia

1University of Naples, Italy 2University of Padova, Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: In the field of innovative anticancer therapies, PEGylated nanoncologicals have attracted significant attention in recent years, due to their ability to deliver selectively one or more drugs directly to solid tumors through passively targeting mechanisms. However, the most common approach to improve their selectivity remains surface decoration with different targeting motifs overexpressed in cancer cells or blood vessels, including antibodies, peptides and small molecules, thus building an actively-targeted nanomedicine. Amid them, folate (Fol) receptor (Fr) is one of the most extensively employed target to enhance nano-carrier accumulation in cancer cells since it is overexpressed on the vast majority of cancer tissues (epithelial, ovarian, cervical, breast, lung, kidney, colorectal, brain). Unfortunately, the extent of targeting ligand presentation at nanoparticle (NP) surface, including Fol-targeted nano-carriers, can be much lower than theoretical, which can result in poor benefits of the targeting approach. Aim: On these premises, in this study we propose a novel strategy to promote Fol exposition on core shell NPs based on amphiphilic block copolymers of poly(caprolactone) (PCL) and polyethylenglycol (PEG), through the aid of (2-hydroxypropyl)-cyclodextrin (HPÃ?²CD), due to its ability to form very stable complex with Fol. Methods: Non-targeted NPs (nt-NPs) and targeted NPs (t-NPs) with and without HPÃ?²CD were prepared by a slightly modified melting/sonication procedure from PCL-PEG and PCL-PEG/PCL-PEG-Fol mixtures, respectively. NPs were characterized for size, morphology, charge, fixed aqueous layer thickness (FALT) and HPÃ?²CD content. Interaction of NPs with a specific antibody against folate (mAb-antiFol) was monitored by isothermal titration calorimetry (ITC). Uptake in FR (+) (KB) and FR (-) (A549) cell lines was finally assessed. Results: All the formulations showed very similar properties in term of size (60-70 nm), poly-dispersity index and zeta potential (slightly negative). tNPs showed the lowest shell thickness (1.3 nm) followed by ntNPs (2.0 nm). Shell thickness increased to 4.1 and 3.3 nm respectively for HPÃ?²CD-modified nt-NPs and tNPs. The reduction of shell thickness in the case of tNPs could be related to a more compact arrangement of PEG fringe due to affinity of Fol for PEG chains. In fact, the hydrophobic nature of Fol moieties probably induces their folding in the PEG coating, thus quashing the possible interaction of Fol-decorated NPs with the target receptor. Conversely, the presence of HPÃ?²CD increases the PEG shell, presumably due to its ability to interact with both PEG chains and Fol, finally promoting targeting ligand exposition on the surface. Surface exposure of Fol on NPs was then evaluated through the binding of mAb-antiFol. Results confirmed that HPÃ?²CD drives the assembling process of PCL-PEG-Fol promoting an extensive exposition of Fol molecules on the surface. Finally, cell studies indicated that the saturation of FR through free Fol significantly inhibited the uptake only of HPÃ?²CD-tNPs and only in FR (+) KB cells. FR was involved in the specific uptake of a fraction of HPÃ?²CDtNPs while a large amount of NPs was taken up via receptor-independent mechanisms. Conclusions: We have demonstrated that the use of HPÃ?²CD can be a suitable strategy to modify shell properties of PEGylated NPs, thus enhancing the targeting ability of Fol-decorated PCL-PEG NPs, designed for the treatment of solid tumors

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “C Conte”
  • BylineArticles whose byline prints “I Fotticchia”
  • BylineArticles whose byline prints “F Moret”
  • BylineArticles whose byline prints “C Giancola”
  • BylineArticles whose byline prints “E Reddi”
  • BylineArticles whose byline prints “F Ungaro”
  • BylineArticles whose byline prints “F Quaglia”